🚀 VC round data is live in beta, check it out!
Pentixapharm Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pentixapharm Holding and similar public comparables like HeartBeam, Nutriband, Mira Pharmaceuticals, Kezar Life Sciences and more.
Pentixapharm Holding Overview
About Pentixapharm Holding
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.
Founded
2019
HQ
Employees
80
Website
Financials (FY)
EV
$46M
Pentixapharm Holding Financials
Pentixapharm Holding reported last fiscal year revenue of $135K and EBITDA of $3M.
In the same fiscal year, Pentixapharm Holding generated ($4M) in gross profit, $3M in EBITDA, and had net loss of ($15M).
Pentixapharm Holding P&L
In the most recent fiscal year, Pentixapharm Holding reported revenue of $135K and EBITDA of $3M.
Pentixapharm Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $135K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (3051%) | XXX | XXX | XXX |
| EBITDA | — | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 2159% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (14899%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($15M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (10884%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pentixapharm Holding Stock Performance
Pentixapharm Holding has current market cap of $54M, and enterprise value of $46M.
Market Cap Evolution
Pentixapharm Holding's stock price is $2.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46M | $54M | -0.7% | XXX | XXX | XXX | $-0.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPentixapharm Holding Valuation Multiples
Pentixapharm Holding trades at 340.8x EV/Revenue multiple, and 15.8x EV/EBITDA.
Pentixapharm Holding Financial Valuation Multiples
As of March 21, 2026, Pentixapharm Holding has market cap of $54M and EV of $46M.
Equity research analysts estimate Pentixapharm Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pentixapharm Holding has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54M | XXX | $54M | XXX | XXX | XXX |
| EV (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 340.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 15.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (11.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (3.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pentixapharm Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pentixapharm Holding Margins & Growth Rates
Pentixapharm Holding's revenue in the last fiscal year grew by 392%.
Pentixapharm Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 392% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 2159% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (143%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 296% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 104% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11848% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pentixapharm Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| HeartBeam | XXX | XXX | XXX | XXX | XXX | XXX |
| Nutriband | XXX | XXX | XXX | XXX | XXX | XXX |
| Mira Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Kezar Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Envoy Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pentixapharm Holding M&A Activity
Pentixapharm Holding acquired XXX companies to date.
Last acquisition by Pentixapharm Holding was on XXXXXXXX, XXXXX. Pentixapharm Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pentixapharm Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPentixapharm Holding Investment Activity
Pentixapharm Holding invested in XXX companies to date.
Pentixapharm Holding made its latest investment on XXXXXXXX, XXXXX. Pentixapharm Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pentixapharm Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pentixapharm Holding
| When was Pentixapharm Holding founded? | Pentixapharm Holding was founded in 2019. |
| Where is Pentixapharm Holding headquartered? | Pentixapharm Holding is headquartered in Germany. |
| How many employees does Pentixapharm Holding have? | As of today, Pentixapharm Holding has over 80 employees. |
| Is Pentixapharm Holding publicly listed? | Yes, Pentixapharm Holding is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Pentixapharm Holding? | Pentixapharm Holding trades under PTP ticker. |
| When did Pentixapharm Holding go public? | Pentixapharm Holding went public in 2024. |
| Who are competitors of Pentixapharm Holding? | Pentixapharm Holding main competitors are HeartBeam, Nutriband, Mira Pharmaceuticals, Kezar Life Sciences. |
| What is the current market cap of Pentixapharm Holding? | Pentixapharm Holding's current market cap is $54M. |
| What is the current revenue of Pentixapharm Holding? | Pentixapharm Holding's last fiscal year revenue is $135K. |
| What is the current EV/Revenue multiple of Pentixapharm Holding? | Current revenue multiple of Pentixapharm Holding is 340.8x. |
| Is Pentixapharm Holding profitable? | No, Pentixapharm Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.